|
10 Dec 2019
|
Sun Pharma Advanced
|
Prabhudas Lilladhar
|
157.21
|
|
163.05
(-3.58%)
|
|
Not Rated
|
|
|
Sun Pharma Advanced Research (SPARC) received a resolution for Abraxane as Abraxis Biosciences LCC withdrew its infringement claims yesterday in the US District Court of New Jersey. Earlier, Abraxis filed a complaint in the court that the NDA (505b2) of SPARC (Abraxane) has breached patent and sued them for its filing of Taclantis (Paclitaxel Injection concentrate for Suspension) in the District Court. While the event is a positive development in February FY20E (filed with USFDA in June2019). SPARC will have three potential annual sales of US$25-30m. Not Rated SPARC evaluating marketing options...
|
|
11 Jun 2015
|
Sun Pharma Advanced
|
Karvy
|
157.21
|
|
398.25
(-60.52%)
|
|
|
|
|
Four New Products Added to Pipeline; Xelpros NDA Submission CompletedSPARC replied to the Complete Response Letter (CRL) from USFDA for Xelpros (Latanoprost BAK-Free) in April 2015, this completes the full submission of NDA for Xelpros.
|
|
11 Jun 2015
|
Sun Pharma Advanced
|
Reliance Securities
|
157.21
|
|
398.20
(-60.52%)
|
|
|
|
|
Sun has discontinued certain programs after commercial assessment of the molecules and found them unviable on economic and commercial standpoints. These include candidates such as Venlafexine ER 300mg, Sun...
|
|
03 Mar 2015
|
Sun Pharma Advanced
|
Karvy
|
157.21
|
|
411.65
(-61.81%)
|
|
|
|
|
Innovating New Drug Delivery Systems and New Drugs: Sun Pharma Advanced Research Company (SPARC) is primarily involved in new drug discovery, research and development, unlike other Indian pharma firms that mainly manufacture generic medicines. SPARC has been granted 20 US patents for various inventions. The company has 11 novel products in pipeline at various development stages for launch in US. Some products have been launched in India.
|